Ketones provide an extra source of fuel for the failing heart without impairing glucose oxidation
- PMID: 38369056
- DOI: 10.1016/j.metabol.2024.155818
Ketones provide an extra source of fuel for the failing heart without impairing glucose oxidation
Abstract
Background: Cardiac glucose oxidation is decreased in heart failure with reduced ejection fraction (HFrEF), contributing to a decrease in myocardial ATP production. In contrast, circulating ketones and cardiac ketone oxidation are increased in HFrEF. Since ketones compete with glucose as a fuel source, we aimed to determine whether increasing ketone concentration both chronically with the SGLT2 inhibitor, dapagliflozin, or acutely in the perfusate has detrimental effects on cardiac glucose oxidation in HFrEF, and what effect this has on cardiac ATP production.
Methods: 8-week-old male C57BL6/N mice underwent sham or transverse aortic constriction (TAC) surgery to induce HFrEF over 3 weeks, after which TAC mice were randomized to treatment with either vehicle or the SGLT2 inhibitor, dapagliflozin (DAPA), for 4 weeks (raises blood ketones). Cardiac function was assessed by echocardiography. Cardiac energy metabolism was measured in isolated working hearts perfused with 5 mM glucose, 0.8 mM palmitate, and either 0.2 mM or 0.6 mM β-hydroxybutyrate (βOHB).
Results: TAC hearts had significantly decreased %EF compared to sham hearts, with no effect of DAPA. Glucose oxidation was significantly decreased in TAC hearts compared to sham hearts and did not decrease further in TAC hearts treated with high βOHB or in TAC DAPA hearts, despite βOHB oxidation rates increasing in both TAC vehicle and TAC DAPA hearts at high βOHB concentrations. Rather, increasing βOHB supply to the heart selectively decreased fatty acid oxidation rates. DAPA significantly increased ATP production at both βOHB concentrations by increasing the contribution of glucose oxidation to ATP production.
Conclusion: Therefore, increasing ketone concentration increases energy supply and ATP production in HFrEF without further impairing glucose oxidation.
Keywords: HFrEF; Ketone oxidation; SGLT2 inhibition.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of competing interest GDL is a shareholder of Metabolic Modulators Research Ltd. and has received grant support from Servier, Boehringer Ingelheim, Sanofi, and REMED Biopharmaceuticals. The other authors have no additional conflicts of interest to disclose.
Similar articles
-
Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond.Cardiovasc Res. 2024 Dec 14;120(16):1996-2016. doi: 10.1093/cvr/cvae231. Cardiovasc Res. 2024. PMID: 39453987 Free PMC article. Review.
-
Increased ketone body oxidation provides additional energy for the failing heart without improving cardiac efficiency.Cardiovasc Res. 2019 Sep 1;115(11):1606-1616. doi: 10.1093/cvr/cvz045. Cardiovasc Res. 2019. PMID: 30778524 Free PMC article.
-
SGLT2 inhibition alters substrate utilization and mitochondrial redox in healthy and failing rat hearts.J Clin Invest. 2024 Dec 16;134(24):e176708. doi: 10.1172/JCI176708. J Clin Invest. 2024. PMID: 39680452 Free PMC article.
-
Ketones can become the major fuel source for the heart but do not increase cardiac efficiency.Cardiovasc Res. 2021 Mar 21;117(4):1178-1187. doi: 10.1093/cvr/cvaa143. Cardiovasc Res. 2021. PMID: 32402081 Free PMC article.
-
Insulin resistance and heart failure during treatment with sodium glucose cotransporter 2 inhibitors: proposed role of ketone utilization.Heart Fail Rev. 2020 May;25(3):403-408. doi: 10.1007/s10741-020-09921-3. Heart Fail Rev. 2020. PMID: 31960270 Review.
Cited by
-
The Off-Target Cardioprotective Mechanisms of Sodium-Glucose Cotransporter 2 Inhibitors: An Overview.Int J Mol Sci. 2024 Jul 14;25(14):7711. doi: 10.3390/ijms25147711. Int J Mol Sci. 2024. PMID: 39062954 Free PMC article. Review.
-
Effect of dapagliflozin on the serum metabolome in patients with type 2 diabetes mellitus.J Diabetes Metab Disord. 2024 Dec 16;24(1):4. doi: 10.1007/s40200-024-01508-1. eCollection 2025 Jun. J Diabetes Metab Disord. 2024. PMID: 39697865
-
Elective peri-operative management of adults taking glucagon-like peptide-1 receptor agonists, glucose-dependent insulinotropic peptide agonists and sodium-glucose cotransporter-2 inhibitors: a multidisciplinary consensus statement: A consensus statement from the Association of Anaesthetists, Association of British Clinical Diabetologists, British Obesity and Metabolic Surgery Society, Centre for Perioperative Care, Joint British Diabetes Societies for Inpatient Care, Royal College of Anaesthetists, Society for Obesity and Bariatric Anaesthesia and UK Clinical Pharmacy Association.Anaesthesia. 2025 Apr;80(4):412-424. doi: 10.1111/anae.16541. Epub 2025 Jan 9. Anaesthesia. 2025. PMID: 39781571 Free PMC article.
-
Cardiac intermediary metabolism in heart failure: substrate use, signalling roles and therapeutic targets.Nat Rev Cardiol. 2025 Jun 22. doi: 10.1038/s41569-025-01166-7. Online ahead of print. Nat Rev Cardiol. 2025. PMID: 40544173 Review.
-
Advances in myocardial energy metabolism: metabolic remodelling in heart failure and beyond.Cardiovasc Res. 2024 Dec 14;120(16):1996-2016. doi: 10.1093/cvr/cvae231. Cardiovasc Res. 2024. PMID: 39453987 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical